Transcript of Investors'' Conference Call for the Quarter ended June 30, 2026

July 27, 2026 BSE Limited National Stock Exchange of India Limited Floor 25, P.J. Tower Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended – Transcript of the Investors’ Conference Call for the Quarter ended June 30, 2026 Dear Sir/Madam, Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we enclose the transcript of Investors’ Conference Call for un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, held on July 23, 2026. The link to access the transcript of the earnings conference call is given below: https://www.jubilantingrevia.com/Uploads/upload/Earning_Call_Transcript.pdf This is for your information and records. Thanking you, Yours faithfully, For Jubilant Ingrevia Limited Deepanjali Gulati Company Secretary & Compliance Officer List of management attendees 1. Mr. Shyam S Bhartia, Chairman 2. Mr. Deepak Jain, CEO and Managing Director 3. Mr. Varun Gupta, CFO – Jubilant Ingrevia Limited 4. Mr. Pavleen Taneja, Head – Investor Relations External participants during Q&A session 1. Siddharth Gadekar, Equirus 2. Abhijit Akella, Kotak Institutional Equities 3. Nitesh Dhoot, Anand Rathi Institutional Equities 4. Archit Joshi, Nuvama Institutional Equities 5. Harsh Shah, Rare Enterprises 6. Rohit Nagraj, 360 One Capital 7. Kiran Gadge, Knightstone Capital Page 1 of 20 Jubilant Ingrevia Limited Q1 FY27 Earnings Conference Call July 23, 2026 Moderator: Ladies and gentlemen, good day, and welcome to Jubilant Ingrevia's Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Pavleen Taneja, Head of Investor Relations at Jubilant Ingrevia Limited. Thank you, and over to you, sir. Pavleen Taneja: Thank you, Rayo. Good evening, everyone. Thank you for joining the Quarter 1 of FY 2027 Earnings Conference Call of Jubilant Ingrevia Limited. I would like to remind you that some of the statements made on the call today could be forward-looking in nature, and a detailed disclaimer in this regard has been included in the press release and results presentation that has been shared on our website. On the call today, we have Mr. Shyam Bhartia, Chairman; Mr. Deepak Jain, CEO and Managing Director; and Mr. Varun Gupta, CFO, Jubilant Ingrevia Limited. I now invite Mr. Shyam Bhartia to share his comments. Shyam Bhartia: Thank you, Pavleen. A very good evening to all of you. We are pleased to report a strong start to FY 2027, delivering healthy financial performance in the first quarter. Revenue grew by 25% year-on- year, while EBITDA increased by 36% year-on-year, reflecting the strength of our business model and disciplined execution across operations. Now let me take you through an update on the markets we operate in. Despite continued geopolitical uncertainties in the Middle East, demand across chemical industry has remained resilient. Industry volumes have Page 2 of 20 stayed stable. While pricing has shown a firming trend in the recent weeks, driven by improving consumption dynamics across key customer segments. Pharmaceuticals continued to be a key growth driver for the company, supported by volume growth and sustained demand across markets. We witnessed a stable momentum in the agrochemicals during the quarter, with demand trends showing encouraging signs of recovery across key segments. Healthy export visibility and improving market dynamics have supported recent price increases. The Nutrition and Personal Care market witnessed healthy growth during the quarter, led by higher realizations for niacinamide and choline. At the same time, volumes remained resilient across end-use segments, underscoring stable market demand. We are also seeing a strong traction with customers in electronic semicon segment who are keen to partner with us for integrated opportunities. Now let me share a few details on our future outlook. We are encouraged by the progress of our Pinnacle journey, which is increasingly reflected in our performance through strong revenue and EBITDA growth and a stronger opportunity pipeline. Supported by sustained volume growth and a firmer pricing, we remain confident of continuing our growth momentum. FY 2027, we expect growth to be led by Specialty Chemicals and Nutrition alongside a recovery in acetyls. We anticipate sequential improvement in revenue and EBITDA over the coming quarters. In the new multipurpose plant remains on track for commissioning by the end of current calendar year, further strengthening of our CDMO and Fine Chemicals growth road map. With this, I hand over to Deepak. Thank you. Deepak Jain: Thank you, Mr. Bhartia. A very good evening to everyone. We appreciate your participation in the Q1 FY27 investor call. During the quarter, we continued to advance our strategic priorities while effectively navigating global challenges. Despite disruptions in the Middle East affecting global supply chains and price dynamics, our diversified sourcing capabilities, customer relationships and operational agility enabled strong business performance and effective cost pass-throughs. The Page 3 of 20 strength of our agile operations and execution capabilities during this challenging period is clearly reflected in our strong Q1 performance. Let me share the overall business update for Q1 FY27 first. Q1 marked a strong start to the year with revenue reaching a 15-quarter high of INR1,300 crore, up 25% year-on-year, driven by healthy volume growth and improved realizations. EBITDA increased to INR209 crore, growing 36% year-on-year and 22% sequentially, while PAT stood at INR106 crore, up 41% year-on-year and 22% quarter-on-quarter. In our Specialty Chemicals business, we delivered revenue of INR533 crore, up 11% year-on-year and 3% sequentially, supported by steady business volumes and robust growth in Fine Chemicals and CDMO businesses. EBITDA stood at INR139 crore with margins of 26%, benefiting from improved pricing and a richer product mix led by value-added CDMO and fine chemical offerings. Our pyridine and picoline business delivered steady volumes during the quarter. Despite some pricing pressure in pyridine, cost optimization initiatives helped sustain a healthy performance. Our Fine Chemicals business delivered strong momentum during the quarter. Pyridine and Diketene derivatives recorded healthy volume growth with improved pricing. In Personal Care, we now have over 20 products under development, and we are seeing increasing traction across key Personal Care segments. In Industrials, we continue to strengthen volumes with existing customers while expanding our new customer pipeline. Our CDMO business continues to gain momentum during the quarter. The agro segment benefited from the rollout of big innovator CDMO volumes, while pharma saw strong customer traction and a more than threefold expansion in the pipeline following our U.S. and Europe roadshow. In semiconductors and electronics, we are building a dedicated R&D and clean room facility at our Greater Noida facility, and we are seeing encouraging growth in our opportunity funnel. Our CDMO and Fine Chemicals pipeline continued to show good momentum. We have a funnel of 100-plus molecules with INR3,500-plus crore of peak revenue potential with now 25-plus confirmed molecules, Page 4 of 20 which will drive our growth in coming years. We added 5 new molecules in the last quarter acros [Showing first 8,000 characters — download PDF for full document]